Systematic Review and Meta-analysis

Pawar Shrikant

Assistant Professor, Claflin University

Research Affiliate, Yale University

Co-founder, ChestAi

https://www.claflin-computation.com/

Study question?

- Selection of population?
- Intervention/exposure?
- Comparator/control?
- Outcomes?

What is systematic review & meta-analysis?

- A literature review that collects and critically analyzes multiple research studies using methods selected a priori, and then analyzes the selected studies.
- Meta-analysis is a method for systematically combining pertinent qualitative and quantitative study data to develop a single conclusion that has a greater statistical power.

Review types

- Narrative review-not organized
- Systematic review- organized
- 1. Scoping review-focused scope
- 2. Rapid review
- 3. Meta-analysis

Research synthesis



©Pawar/Claflin University

How to select topics for systematic review?

- Timely topics
- Topics with multiple studies
- Topics with conflicting results

Types of systematic reviews

- Descriptive
- Diagnostic accuracy
- Effects of intervention

Descriptive



66 Get citation 💿 CC-BY 4.0 🔟 Stats

EDITORIAL

March/2020 vol. 18

 $\langle \rangle$

COVID-19 and smoking: A systematic review of the evidence

Constantine I. Vardavas ^{1,2} 🖂, Katerina Nikitara ²

More details

Tob. Induc. Dis. 2020;18(March):20

> DOI: https://doi.org/10.18332/tid/119324

🕒 Article (PDF)

References (13) Citations (793)

The views and opinions expressed in this article are strictly those of the author(s).

KEYWORDS

tobacco • smoking • COVID-19 • coronavirus

TOPICS

Diseases, due to tobacco

COVID-19 is a coronavirus outbreak that initially appeared in Wuhan, Hubei Province, China, in December 2019, but it has already evolved into a pandemic spreading rapidly worldwide^{1,2}. As of 18 March 2020, a total number of 194909 cases of COVID-19 have been reported, including 7876 deaths, the majority of which have been reported in China (3242) and Italy (2505)³.

However, as the pandemic is still unfortunately under progression, there are limited data with regard to the clinical characteristics of the patients as well as to their prognostic factors⁴. Smoking, to date, has been assumed to be possibly associated with adverse disease prognosis, as extensive evidence has highlighted the negative impact of tobacco use on lung health and its causal association with a plethora of respiratory diseases⁵. Smoking is also detrimental to the immune system

Diagnostic accuracy

Int J Immunopathol Pharmacol. 2022 Jan-Dec; 36: 03946320221115316. Published online 2022 Jul 15. doi: <u>10.1177/03946320221115316</u> PMCID: PMC9289644 PMID: <u>35840546</u>

Go to:)

COVID-19: Clinical laboratory diagnosis and monitoring of novel coronavirus infected patients using molecular, serological and biochemical markers: A review

<u>Ghulam Rasool</u>,¹ <u>Muhammad Riaz</u>,^{⊠1} <u>Mazhar Abbas</u>,² <u>Hina Fatima</u>,^{3,4} <u>Muhammad Mustafa Qamar</u>,¹ <u>Farzana Zafar</u>,⁴ and <u>Zahed Mahmood</u>⁵

Author information ► Article notes ► Copyright and License information <u>PMC Disclaimer</u>

Abstract

COVID-19, a novel coronavirus disease, has provoked a variety of health and safety concerns, and socioeconomic challenges around the globe. The laboratory diagnosis of SARS-CoV-2 was quickly established utilizing nucleic acid amplification techniques (NAAT) after the disease causing virus has been identified, and its genetic sequence has been determined. In addition to NAAT, serological tests based on antibodies testing against SARS-CoV-2 were introduced for diagnostic and epidemiologic studies. Other biochemical investigations include monitoring of peripheral blood cells count, platelets/lymphocyte ratio, coagulation profile, cardiac, and inflammatory markers such as cytokines storm are also crucial in combating COVID-19 pandemic. Further, accurate and reliable laboratory results for SARS-CoV-2 play very important role in the initiation of early treatment and timely management of COVID-19 patients, provide support in clinical decision-making process to control infection, and detection of asymptomatic cases. The Task Force on Coronavirus-19 constituted by International Federation of Clinical

Effects of intervention



International Immunopharmacology Volume 83, June 2020, 106455



The possible of immunotherapy for COVID-19: A systematic review

Akram AminJafari ^a, Sorayya Ghasemi ^{b c} 🝳 🖂

Show more 🗸

+ Add to Mendeley 😤 Share 🍠 Cite

https://doi.org/10.1016/j.intimp.2020.106455 🫪

Get rights and content 🛪

Highlights

- The <u>immunotherapy</u> is an effective method for SARS-CoV, and MERS-CoV.
- The immunotherapies include vaccines, <u>monoclonal antibody</u> candidates, and etc.
- There is no serious immunotherapy research for COVID-19.
- Similar studies on the <u>coronaviruses</u> showed notable results.
- So immunotherapy for COVID-19 <u>virus</u> can also be a suitable option.

Conducting a systematic review

- Develop a specific research question
- Draft the search strategy: Keywords, inclusion, exclusion criteria's, limits
- Register your reviews: Example Prospero: International prospective register for systematic reviews
- Systematic search for data, check the data and articles sources (PubMed, EMBASE, Google scholar, etc.)

Continued:

 Controlled vocabulary (MeSH Headlines). <u>https://www.ncbi.nlm.nih.gov/mesh/</u>

NIH National Library of Medi	cine ^{ation}	👤 spawar@claflin.edu
MeSH	ed	Search Help
	MeSH (Medical Subject Headings) is the NLM controlled PubMed.	vocabulary thesaurus used for indexing articles for
Using MeSH	More Resources	
Help	<u>E-Utilities</u>	
Tutorials	NLM MeSH Homepage	

Continued:

• Example Hemorrhage vs Brain Hemorrhage, check the differences.

MeSH	MeSH	✓ hemorrhage		Search	
		Create alert Limits Advance	bed		Help
Summary - 20	per page 👻		Send to: +	PubMed Search Builder	
Search resul	lts				
Items: 1 to 20	of 44		<< First < Prev Page 1 of 3 Next > Last >>		
 Hemorrha Bleeding or 	Ige r escape of blood from a	a vessel.	l	Add to search builder AND ~ Search PubMed	
 Intracrania Bleeding w ARTERIOS THALAMU Year introduct 	Il Hemorrhage, Hyperte vithin the SKULL that is c SCLEROSIS. Hypertensi IS; but may also involve ced: 2000	ansive caused by systemic HYPERTENSIC ive hemorrhages are most frequent the CEREBRAL CORTEX, subcorti	DN, usually in association with INTRACRANIAL in the BASAL GANGLIA; CEREBELLUM; PONS; and cal white matter, and other brain structures.	You [] Find related data Database: Select ~ Find items	ttorial
 Subarachn Bleeding in moderate t 	noid Hemorrhage, Trau Into the SUBARACHNOIE to severe hemorrhages n	matic D SPACE due to CRANIOCEREBR may be associated with INTRACRA	AL TRAUMA. Minor hemorrhages may be asymptomatic; NIAL HYPERTENSION and VASOSPASM, INTRACRANIAL.	Search details	
Year introduc	ced: 2000 n Hemorrhage , Trauma	tic		"hemorrhage"[MeSH Terms] OR hemorrhage[Text Word]	ł



PubMed Search Builder

PubMed Search Builder	
Add to search builder $AND \lor$	
Search PubMed	
You Tube Tute	orial
Find related data Database: Select	
Search details	
"intracranial hemorrhages"[MeSH Terms] OR Brain hemorrhage[Text Word]	
Search See mo	ore

MeSH disadvantages

- Title
- Authors and affiliations
- Abstract
- MeSH terms
- Try also google scholar

Full 🗸

Send to: -

Brain Hemorrhage, Traumatic

Bleeding within the brain as a result of penetrating and nonpenetrating CRANIOCEREBRAL TRAUMA. Traumatically induced hemorrhages may occur in any area of the brain, including the CEREBRUM; BRAIN STEM (see BRAIN STEM HEMORRHAGE, TRAUMATIC); and CEREBELLUM. Year introduced: 2000

PubMed search builder options Subheadings:

blood	enzymology	pathology
Cerebrospinal fluid	epidemiology	physiopathology
Chemically induced	ethnology	prevention and control
□ classification	etiology	psychology
complications	genetics	radiotherapy
□ congenital	☐ history	rehabilitation
diagnosis	immunology	surgery
diagnostic imaging	metabolism	□ therapy
□ diet therapy	microbiology	🗆 urine
□ drug therapy	mortality	veterinary
embryology	parasitology	

Restrict to MeSH Major Topic.

 \Box Do not include MeSH terms found below this term in the MeSH hierarchy.

Tree Number(s): C10.228.140.199.275, C10.228.140.300.535.450.200, C10.900.300.087.187, C10.900.300.837.150, C14.907.253.573.400.150, C26.915.300.200.175, C26.915.300.490.150

MeSH Unique ID: D020201

Int J Immunopathol Pharmacol. 2022 Jan-Dec; 36: 03946320221115316. Published online 2022 Jul 15. doi: <u>10.1177/03946320221115316</u>

PMCID: PMC9289644 PMID: <u>35840546</u>

COVID-19: Clinical laboratory diagnosis and monitoring of novel coronavirus infected patients using molecular, serological and biochemical markers: A review

<u>Ghulam Rasool</u>,¹ <u>Muhammad Riaz</u>,²¹ <u>Mazhar Abbas</u>,² <u>Hina Fatima</u>,^{3,4} <u>Muhammad Mustafa Qamar</u>,¹ <u>Farzana Zafar</u>,⁴ and <u>Zahed Mahmood</u>⁵

► Author information ► Article notes ► Copyright and License information PMC Disclaimer

Abstract

Go to: >

COVID-19, a novel coronavirus disease, has provoked a variety of health and safety concerns, and socioeconomic challenges around the globe. The laboratory diagnosis of SARS-CoV-2 was quickly established utilizing nucleic acid amplification techniques (NAAT) after the disease causing virus has been identified, and its genetic sequence has been determined. In addition to NAAT, serological tests based on antibodies testing against SARS-CoV-2 were introduced for diagnostic and epidemiologic studies. Other biochemical investigations include monitoring of peripheral blood cells count, platelets/lymphocyte ratio, coagulation profile, cardiac, and inflammatory markers such as cytokines storm are also crucial in combating COVID-19 pandemic. Further, accurate and reliable laboratory results for SARS-CoV-2 play very important role in the initiation of early treatment and timely management of COVID-19 patients, provide support in clinical decision-making process to control infection, and detection of asymptomatic cases. The Task Force on Coronavirus-19 constituted by International Federation of Clinical

Data collection process:

Identification			
Records	Screening		
identified	Records	Eligibility	
database search, remove duplicates	screened on selection criteria, wrong cohort, outcome, study design	Case reports, reviews, outcome of interests, no comparable cohorts	

Example of final inclusion:



Reddy, R. K., Charles, W. N., Sklavounos, A., Dutt, A., Seed, P. T., & Khajuria, A. (2021). The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. Journal of medical virology, 93(2), 1045–1056. https://doi.org/10.1002/jmv.26389

	Setting	Study design	Number of centers	Study period	Number of patients, current smokers vs former/never- smokers	Number of patients, any smoking history vs never- smokers	Study qualit
Azar et al ²²	United States	Cohort	24	Jan- Apr	10 vs 216	73 vs 153	Fair
Bhargava et al ²³	United States	Cohort	1	Mar- Apr	11 vs 186		Good
Bi et al ²⁴	China	Cohort	1	Jan- Mar	8 vs 105		Good
Brenner et al ²⁵	International	Cohort	1+	-Apr	11 vs 150		Poor
Buckner et al ²⁶	United States	Case series	3	Mar- May		22 vs 64	Poor
CDC COVID-19 Response	United States	Cohort	1+	Feb- Mar	27 vs 1467	105 vs 1389	Poor

Continued:

Reddy, R. K., Charles, W. N., Sklavounos, A., Dutt, A., Seed, P. T., & Khajuria, A. (2021). The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. Journal of medical virology, 93(2), 1045–1056. https://doi.org/10.1002/jmv.26389

Meta-analysis

- Systematic review: Qualitative summary
- Meta-analysis: Quantitative summary

When to perform and avoid Meta-analysis?

- Perform: Multiple high-quality studies: similar design, population, control, outcomes.
- Avoid: Heterogeneous studies/too many variable outcomes to compare, too few studies, and low-quality studies (small sample sizes, high variability, missing values)

How to visualize meta-analysis results?

 Forest Plots are typically used to display epidemiological data and are often used in subject area reviews to summarize previously published findings. The forest plot is not necessarily a meta-analytic technique but may be used to display the results of a meta-analysis or as a tool to indicate where a more formal meta-analytic evaluation may be useful.

Forest Plot

R Library *"forestploter"* focuses entirely on forest plots, which are treated as a table.

https://cran.r-project.org/web/packages/

Forest plot based on ratios



Graphical Depictions of Toxicological Data G.M. Woodall, in Encyclopedia of Toxicology (Third Edition), 2014

Diabetes

Meta-analysis steps

- Identify outcomes to be reported
- Identify comparisons to be made
- Determine statistics to use
- Extract data from each study
- Combine results to obtain results summary
- Understand the differences amongst studies

Heterogeneity examples:

- Clinical
- 1. Participant characteristics
- 2. Exposures/interventions
- 3. Outcomes
- Methodological
- 1. Study design
- 2. Study quality
- Statistical

Want to collaborate?

• Google scholar:

https://scholar.google.com/citations?user=SvcIPSsAAAAJ&hl=en

holar google com/citations?user=SvcIPSsAAAA.I&hl=e

Google Scholar

- Contact: <u>Shrikant.pawar@yale.edu</u>
- Thanks!

	Shrikant Pawar MS, Ph.D.		FOLLOW	GET MY OWN	PROFILE
	Assistant Professor, Claffin University: Co-founder, ChestAi.org; Research Affilia Verified email at yale.edu - <u>Homepage</u> Bioinformatics Computational Biology Computer Science	ate, <u>Yale</u>		Cited by	
					All Since 2018
TITLE		CITED BY	YEAR	Citations 414 h-index 2	19 4118 27 27
Causes of blindne of avoidable blind ID Steinmetz, RRA E The Lancet Global He	ass and vision impairment in 2020 and trends over 30 years, and prevalence Iness in relation to VISION 2020: the Right to Sight: an analysis oume, PS Braint, SK Flaxman, HRB Taylor, ath 9(2), e14-e160	997	2021	i10-index 4	2100
Hearing loss prev Burden of Diseas LM Haile, K Kameno The Lancet 397 (102	valence and years lived with disability, 1990–2019: findings from the Global e Study 2019 r, PS Bnant, AU Orji, JD Steinmetz, A Abdoli, R), 969-1009	444	2021		1575
Spatial, temporal attributable disea MB Reitsma, PJ Ken The Lancet 397 (102	, and demographic patterns in prevalence of smoking tobacco use and se burden in 204 countries and territories, 1990–2019: a systematic drick, E Ababrah, C Abafati, M Abbasi-Kangevari, 22, 237-260	359	2021	2017 2018 2019 2020	2021 2022 2023
Global mortality a Global Burden of GBDAR Collaborator	associated with 33 bacterial pathogens in 2019: a systematic analysis for the Disease Study 2019 s	308	2022	Public access	VIEW ALI
Clobal regional	and national program towards Sustainable Development Coal 2.2 for	202	2004	not available	available
Bobal, regional, neonatal and chil BBDUM Collaborator The Lancet	d health: all-cause and cause-specific mortality findings from the Global s	202	2021	Based on funding mandate	95
Population-level in systematic analyse D Bryazka, MB Reits The Lancet 400 (103	isks of alcohol consumption by amount, geography, age, sex, and year: a sis for the Global Burden of Disease Study 2020 ma, MG Griswold, KH Abate, C Abbafati, 47/, 185-235	162	2022	Co-authors	VIEWALL
Curcumin in com	bination with anti-cancer drugs: A nanomedicine review	128	2019	Chandrajit Lahiri Professor, Dept. o	f Biotechnology
H Batra, S Pawar, D Pharmacological Res	Bahl learch 139, 91-105			Aditya Stanam University of Iowa)
KIFCI, a novel puporotein interaction	tative prognostic biomarker for ovarian adenocarcinomas: delineating n networks and signaling circuitries	97	2014	Ritu Aneja Professor of Canc	er Biology, Uni
Journal of ovarian res	search 7, 1-9			A Padmashree C. G	Rida